MEK inhibitors are being evaluated for their clinical efficacy in targeting CRC with KRAS mutations and have a greater dependence on MAPK pathway signaling [18]; however, it seems that MAPK pathway inhibition during the treatment of CRC with KRAS mutation remains elusive [6, 19, 20]. This evidence concerns the gene MAP2K7 and colorectal carcinoma.